Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29823712 | 1.00 | ENPP2 (0.38) | ENPP2L3MBTL1ALDH1A1MMP2TSHR | |
| SCHEMBL29515564 | 0.78 | P2RX7 (0.41) | ENPP2L3MBTL1ALDH1A1HTTSLC6A2 | |
| SCHEMBL29232877 | 0.78 | ENPP2 (0.37) | ENPP2L3MBTL1MMP2TSHRHTT | |
| SCHEMBL586439 | 0.78 | P2RX7 (0.41) | ENPP2L3MBTL1ALDH1A1HTTSLC6A2 | |
| SCHEMBL28165 | 0.76 | NAPRT (0.45) | ENPP2L3MBTL1LIPEHSP90AA1NPC1 | |
| SCHEMBL29952309 | 0.76 | NOS3 (0.52) | ENPP2ALDH1A1HSP90AA1NOS3NOS1 | |
| SCHEMBL1920925 | 0.76 | TRIM24 (0.47) | ENPP2L3MBTL1HTTLIPEHSP90AA1 | |
| SCHEMBL117563 | 0.76 | NOS3 (0.52) | ENPP2ALDH1A1HSP90AA1NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL14797461 | 0.76 | P2RX7 (0.40) | ENPP2L3MBTL1ALDH1A1HTTSLC6A2 | |
| SCHEMBL315754 | 0.76 | SMN1; SMN2 (0.45) | ENPP2ALDH1A1HTTNPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20250206757-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | GASHERBRUM BIO, INC. | 2025-06-26 | — | — | US | disclosed |
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-12291538-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-06 | — | — | US | disclosed |
| EP-4496797-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | Gasherbrum Bio, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| CN-118359538-A | Isoquinoline compound, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-04-25 | — | — | US | disclosed |
| CN-112888696-B | Exonuclease inhibitors and methods of use thereof | 德琪医疗有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240092744-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL R&D CO., LTD (CN) | 2024-03-21 | — | — | US | disclosed |
| US-20240083913-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | MERCK SHARP & DOHME LLC | 2024-03-14 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20100239527-A1 | 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2197842-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-06-23 | — | — | EP | disclosed |
| EP-2195317-A1 | 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
| EP-2064180-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2009032125-A1 | 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032116-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032124-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008082484-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | ENPP2 17/4885L3MBTL1 4683/4885ALDH1A1 527/4885 |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | ENPP2 1483/4885L3MBTL1 995/4885ALDH1A1 1792/4885 |
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | ENPP2 3262/4885L3MBTL1 1874/4885ALDH1A1 4287/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | ENPP2 17/4885L3MBTL1 4683/4885ALDH1A1 527/4885 |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | ENPP2 2861/4885L3MBTL1 2367/4885ALDH1A1 248/4885 |
| US-20240092744-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GOT2, HADH, CYP4A11 | ENPP2 2038/4885L3MBTL1 1801/4885ALDH1A1 52/4885 |
| US-20250206757-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | GLP1R, IAPP, GPR119 | ENPP2 298/4885L3MBTL1 3471/4885ALDH1A1 1791/4885 |
| US-20240083913-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | KRAS, NRAS, HRAS | ENPP2 3262/4885L3MBTL1 1874/4885ALDH1A1 4287/4885 |
| US-12291538-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | ENPP2 3262/4885L3MBTL1 1874/4885ALDH1A1 4287/4885 |
| US-20100239527-A1 | 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | HAVCR2, AZI2, ZC3HAV1 | ENPP2 795/4885L3MBTL1 1514/4885ALDH1A1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.